Pathways to diagnosis of pediatric TB patients: A mixed methods study from India.


Journal

The Indian journal of tuberculosis
ISSN: 0019-5707
Titre abrégé: Indian J Tuberc
Pays: India
ID NLM: 0373027

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 06 05 2020
revised: 11 11 2020
accepted: 28 12 2020
entrez: 8 6 2021
pubmed: 9 6 2021
medline: 27 11 2021
Statut: ppublish

Résumé

A significant proportion of pediatric tuberculosis (TB) patients go unnotified due to the challenges in diagnosis of TB among children. The experiences of this vulnerable group while going through the TB care cascade remain largely undocumented. The aim of this study was to explore the experiences of pediatric TB patients and families along the pathway to TB diagnosis and appropriate treatment in four cities of India. The study used a mixed methods, single phased, embedded design. The primary qualitative and secondary quantitative data were collected simultaneously by interviewing families of 100 randomly selected Xpert MTB/RIF positive pediatric TB patients, under the pediatric TB project, in 4 Indian cities using a semi-structured questionnaire. The qualitative component was analyzed to deduce patterns and themes on the patient and family experiences. Descriptive statistics were used to quantify various events along the TB care pathway including various delays (patient, diagnosis and total) and number of providers visited by patients during the diagnostic process. The median patient, diagnostic and total delays were 3 (IQR: 2,5), 39 (IQR: 23, 91) and 43 days (IQR: 28.5, 98.5), respectively. Patients visited a median of 3 (IQR: 2,4) providers before accessing Xpert MTB/RIF testing. On an average, 68.4% of physicians ordered any test most of them being irrelevant for TB diagnosis. Qualitative data showed considerable suffering for children and their families before and after TB diagnosis including serious concerns of stigma, disruption in education and social life and recurrence of the disease. Our study highlights the significant physical and social distress that the children with TB and their families undergo along the TB care pathway. It also shows diagnostic delay in excess of a month during which multiple providers were met and the patients underwent several diagnostic tests, most of them being inappropriate. Efforts to make Xpert MTB/RIF testing more accessible and part of physicians' toolkit will be of considerable value to ease the complexity of TB diagnosis in children. In addition, communication strategy needs to be developed and implemented to generate awareness among general population around pediatric TB and its management.

Sections du résumé

BACKGROUND BACKGROUND
A significant proportion of pediatric tuberculosis (TB) patients go unnotified due to the challenges in diagnosis of TB among children. The experiences of this vulnerable group while going through the TB care cascade remain largely undocumented. The aim of this study was to explore the experiences of pediatric TB patients and families along the pathway to TB diagnosis and appropriate treatment in four cities of India.
METHODS METHODS
The study used a mixed methods, single phased, embedded design. The primary qualitative and secondary quantitative data were collected simultaneously by interviewing families of 100 randomly selected Xpert MTB/RIF positive pediatric TB patients, under the pediatric TB project, in 4 Indian cities using a semi-structured questionnaire. The qualitative component was analyzed to deduce patterns and themes on the patient and family experiences. Descriptive statistics were used to quantify various events along the TB care pathway including various delays (patient, diagnosis and total) and number of providers visited by patients during the diagnostic process.
RESULTS RESULTS
The median patient, diagnostic and total delays were 3 (IQR: 2,5), 39 (IQR: 23, 91) and 43 days (IQR: 28.5, 98.5), respectively. Patients visited a median of 3 (IQR: 2,4) providers before accessing Xpert MTB/RIF testing. On an average, 68.4% of physicians ordered any test most of them being irrelevant for TB diagnosis. Qualitative data showed considerable suffering for children and their families before and after TB diagnosis including serious concerns of stigma, disruption in education and social life and recurrence of the disease.
CONCLUSION CONCLUSIONS
Our study highlights the significant physical and social distress that the children with TB and their families undergo along the TB care pathway. It also shows diagnostic delay in excess of a month during which multiple providers were met and the patients underwent several diagnostic tests, most of them being inappropriate. Efforts to make Xpert MTB/RIF testing more accessible and part of physicians' toolkit will be of considerable value to ease the complexity of TB diagnosis in children. In addition, communication strategy needs to be developed and implemented to generate awareness among general population around pediatric TB and its management.

Identifiants

pubmed: 34099202
pii: S0019-5707(20)30323-1
doi: 10.1016/j.ijtb.2020.12.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

363-373

Informations de copyright

Copyright © 2021 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors have none to declare

Auteurs

Neeraj Raizada (N)

Foundation for Innovative New Diagnostics, New Delhi, India.

Andrew McDowell (A)

Tulane University, New Orleans, LA, USA.

Debadutta Parija (D)

Foundation for Innovative New Diagnostics, New Delhi, India.

K S Sachdeva (KS)

Central TB Division, Government of India, New Delhi, India.

Sunil D Khaparde (SD)

Central TB Division, Government of India, New Delhi, India.

Raghuram Rao (R)

Central TB Division, Government of India, New Delhi, India.

T N Pavani (TN)

Foundation for Innovative New Diagnostics, New Delhi, India.

S Sudha (S)

Foundation for Innovative New Diagnostics, New Delhi, India.

Himshweta Tyagi (H)

Foundation for Innovative New Diagnostics, New Delhi, India.

Y Mary Rebecca (YM)

Foundation for Innovative New Diagnostics, New Delhi, India.

Sophie Huddart (S)

McGill University, Montreal, Canada.

Virender Singh Salhotra (VS)

Central TB Division, Government of India, New Delhi, India.

Sreenivas Achuthan Nair (SA)

Stop TB Partnership, Geneva, Switzerland.

Claudia M Denkinger (CM)

Foundation for Innovative New Diagnostics, Geneva, Switzerland.

Sarabjit Singh Chadha (SS)

Foundation for Innovative New Diagnostics, New Delhi, India.

Sanjay Sarin (S)

Foundation for Innovative New Diagnostics, New Delhi, India.

Aakshi Kalra (A)

Foundation for Innovative New Diagnostics, New Delhi, India. Electronic address: draakshikalra@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH